Text Size

Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

This study is currently recruiting participants.
Verified June 2012 by University of Malaya
Sponsor:
Information provided by (Responsible Party):
University of Malaya
ClinicalTrials.gov Identifier:
NCT01626339
First received: June 20, 2012
Last updated: June 21, 2012
Last verified: June 2012
History of Changes
  Purpose

Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE).

Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye


Condition Intervention
Age Related Macular Degeneration
 Drug: Intravitreal Ranibizumab
Drug: Intravitreal bevacizumab

Study Type: Interventional
Official Title: Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Malaya:

Estimated Enrollment: 30
Study Start Date: April 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Intravitreal Ranibizumab
    Other Name: Lucentis
    Drug: Intravitreal bevacizumab
    Other Name: Avastin
  Eligibility

Ages Eligible for Study:   20 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

• Patients who wish and need bevacizumab or ranibizumab treatment for underlying disease

Exclusion Criteria:

  • History of previous systemic or ocular Anti-VEGF therapy
  • History of previous intravitreal injection with any drug
  • Intraocular pressure ≥ 22
  • Glaucoma
  • History or presence of thromboembolic events
  • Un-controlled blood pressure
  • Blood donation during the previous 3 weeks
  • Relevant media opacity of the lens
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01626339

Contacts
Contact: Mohammadreza Peyman, MD 0060173387260 ext 1 drmpeyman@yahoo.com
Contact: Visvaraja Subrayan, Prof d.visva@hotmail.com

Locations
Malaysia
University of Malaya Medical Center Recruiting
Kuala Lumpur, Malaysia, 59100
Contact: Mohammadreza Peyman, MD     0060173387260     drmpeyman@yahoo.com    
Sponsors and Collaborators
University of Malaya
  More Information

No publications provided

Responsible Party: University of Malaya
ClinicalTrials.gov Identifier: NCT01626339     History of Changes
Other Study ID Numbers: PPUM/MDU/300/04/03
Study First Received: June 20, 2012
Last Updated: June 21, 2012
Health Authority: Malaysia: Institutional Review Board

Keywords provided by University of Malaya:
Anti vascular endothelial growth factor
retinal vessels

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Mitogens
Endothelial Growth Factors
Bevacizumab
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
 Pharmacologic Actions
Growth Substances
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 23, 2013